Pathological Complete Response to a KEYNOTE-522-Based Neoadjuvant Regimen in Synchronous Bilateral Breast Cancer with Discordant Subtypes: A Case Report
Case Reports in Oncology · 05.11.2026
DOI: 10.1159/cro/abzag094 ↗Kurz gefasst
Fallbericht in der Zeitschrift Case Reports in Oncology, online erschienen am 05.11.2026. Verfasst von Akane Ito und 5 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
A 50-year-old woman was diagnosed with synchronous bilateral breast cancer; triple-negative breast cancer (TNBC) in the right breast and luminal HER2-positive breast cancer in the left breast. Neoadjuvant chemotherapy using the KEYNOTE-522 regimen combined with pembrolizumab resulted in a pathological complete response (pCR) in both tumors. Next-generation sequencing (NGS) performed on pretreatment biopsy specimens identified a pathogenic BRCA1 variant in both tumors. The right tumor showed a high homologous recombination deficiency (HRD) score. These molecular findings provide a potential biological rationale for the observed sensitivity to platinum-containing chemoimmunotherapy, though further studies are required to validate this association.
Zitieren
APA
Ito, A., Kawami, H., Harada, O., Kitada, M., Nishihara, H., & Kato, Y. (2026). Pathological Complete Response to a KEYNOTE-522-Based Neoadjuvant Regimen in Synchronous Bilateral Breast Cancer with Discordant Subtypes: A Case Report. Case Reports in Oncology. https://doi.org/10.1159/cro/abzag094
Vancouver
Ito A, Kawami H, Harada O, Kitada M, Nishihara H, Kato Y. Pathological Complete Response to a KEYNOTE-522-Based Neoadjuvant Regimen in Synchronous Bilateral Breast Cancer with Discordant Subtypes: A Case Report. Case Reports in Oncology. 2026. doi:10.1159/cro/abzag094
BibTeX
@article{Ito2026,
author = {Ito, Akane and Kawami, Hiroyuki and Harada, Oi and Kitada, Masahiro and Nishihara, Hiroshi and Kato, Yasutaka},
title = {Pathological Complete Response to a KEYNOTE-522-Based Neoadjuvant Regimen in Synchronous Bilateral Breast Cancer with Discordant Subtypes: A Case Report},
journal = {Case Reports in Oncology},
year = {2026},
doi = {10.1159/cro/abzag094}
}
EUVIMED